Meyka Pro is live. Get 50% off your first 3 months.Get Started →
Meyka Pro banner
Moderna, Inc.

Moderna, Inc. (MRNA) Stock Overview

Explore Moderna, Inc.’s financial performance, market position, analyst ratings, and future outlook.

MRNA●NASDAQ
HealthcareBiotechnology
$200.10
$2.53(1.25%)
U.S. Market opens in 19h 9m

Moderna, Inc. (MRNA)

Meyka AI Score

Z

Key Financials

Market Cap79.9B
P/E Ratio-24.82
EPS (TTM)$-8.15
ROE-0.39%
Fundamental Analysis

AI Price Forecasts

1 Month$199.05
3 Months$112.87
1 Year Target$100.66

MRNA Stock Analysis & Investment Overview (NASDAQ)

Our AI-powered analysis of Moderna, Inc. (NASDAQ: MRNA) gives investors deep insight into how the stock performs on the NASDAQ exchange, its growth potential, and its market positioning. With a Meyka AI Score of B, Moderna, Inc.'s NASDAQ-listed shares demonstrate moderate investment characteristics based on our machine learning models.

The current technical analysis of MRNA on the NASDAQ shows an RSI of 50.23, suggesting the stock is in a a neutral condition. Our forecasting models predict a 12-month price target of $100.66 for the NASDAQ listing.

Key metrics behind Moderna, Inc.'s NASDAQ-traded stock include a P/E ratio of -24.82 and a market capitalization of 79.9B. Combined with our AI analysis, these give both institutional and retail investors a clear view of MRNA on the NASDAQ.

Price Performance (NASDAQ: MRNA)

1-Day Change
-1.25%
5-Day Change
-14.85%
1-Month Change
9.88%
3-Month Change
250.93%
6-Month Change
278.62%
Year-to-Date (YTD) Change
578.54%
1-Year Change
662.29%
3-Year Change
154.45%
5-Year Change
-42.76%
All-Time (Max) Change
975.81%

Contact Information

https://www.modernatx.com
617 714 6500
325 Binney Street, Cambridge, MA, 02142

Company Facts

47,000 Employees
IPO DateDec 7, 2018
CountryUS
Actively Trading

Frequently Asked Questions